Table 2.
Summary of nanofibers (NFs) and microspheres
Vectors | Delivery mode | Advantages | Drawbacks | Examples | Mechanism | Effects |
---|---|---|---|---|---|---|
Nanofibers (NFs) | Surface adsorption or nanofiber encapsulation | Excellent ability to capture drugs; high specific surface area and porosity; ability to promote osteogenic differentiation and adhesion of BMSCs together with drug delivery | Lack of tissue-specific delivery, resulting in off-target effects and cytotoxicity; weak intracellular uptake | Gelatin nanofibers/miR-29 inhibitors (James et al., 2014) | Upregulate the mRNA levels of both IGF-1 and TGF-β1 | Increase the synthesis of osteonectin and type I collagen |
Polycaprolactone (PCL) nanofibers/siRNA-MSN@PEI (Pinese et al., 2018) | Silence the expression of COLL1A1 | Inhibit fibrous capsule formation to promote host-implant integration | ||||
Microspheres | Surface adsorption or encapsulation inside the microsphere | Sustained drug release; targeted drug delivery; biocompatibility and biodegradability; improved drug efficacy and patient compliance; prevention of nuclease degradation | Sudden release phenomenon in clinical applications; difficulty in large-scale preparation; biocompatibility issues of modified microspheres | Degradable polymer microspheres/miR-26a (Zhang et al., 2016) | Inhibit the expression of Gsk-3β | Promote bone regeneration |